Elsaad products
Member Login

New Products
Our Products
Product Name
Chemical Name
Olopatadine HCl
Therapeutic Category
Ophthalmic drugs
Pharmacologic Category
Histamine H1; Antagonist - Histamine H1; Antagonist, Second Generation - Piperidine Derivative
Pharmaceutical Form
Eye Drops
Olopatadine HCl 1.11 mg EQ.V TO Olopatadine 1mg / Olopatadine HCl 2.22 mg EQ.V TO Olopatadine 2mg
Monitoring Parameters
Dosing: Adult
Allergic conjunctivitis: Ophthalmic:
Olopatadine 1 MG/ML : Instill 1drop into affected eye(s) twice daily (allowing 6-8 hours between doses); results from an environmental study demonstrated that olopatadine was effective when dosed twice daily for up to 6 weeks
Olopatadine 2 MG/ML: Instill 1 drop into affected eye(s) once daily
Dosing: Pediatric
Allergic conjunctivitis: Ophthalmic: Children ≥3 years: Refer to adult dosing.
Treatment of the signs and symptoms of allergic conjunctivitis
Adverse Reactions
Central nervous system: Cold syndrome (up to 10%), headache (up to 7%)
Respiratory: Pharyngitis (up to 10%)
Gastrointestinal: Nausea, taste perversion
Neuromuscular & skeletal: Back pain, weakness
Ocular: Blurred vision, burning, conjunctivitis, dry eyes, eye pain, eyelid edema, foreign body sensation, hyperemia, itching, keratitis, ocular pruritus, stinging
Respiratory: Cough, rhinitis, sinusitis
Miscellaneous: Flu-like syndrome, hypersensitivity, infection
Hypersensitivity to olopatadine hydrochloride or any component of the formulation
Warnings / Precautions Drug
Other warnings/precautions:
• Contact lens: Not for use to treat contact lens-related irritation. Solution contains benzalkonium chloride; remove lens prior to administration and wait at least 10 minutes before reinserting. Do not use contact lenses if eyes are red.
There are no known significant interactions.
Pregnancy Implications
Teratogenic effects were not observed in animal studies; however, a decrease in fetal weight and a decrease in live births were observed. There are no adequate and well-controlled studies in pregnant women.
Excretion in breast milk unknown/use caution
Mechanism of Action
Selective histamine H1-antagonist; inhibits release of histamine from mast cells. Inhibits histamine induced effects on conjunctival epithelial cells.
Pharmacodynamics / Kinetics
Absorption: Low systemic absorption
Protein binding: ~55% (primarily albumin)
Metabolism: Not extensively metabolized
Half-life elimination: ~3 hours
Excretion: Urine (60% to 70%, mostly as unchanged drug); feces (17%)
Powered by: TSS-EST.COM